{
    "clinical_study": {
        "@rank": "80537", 
        "arm_group": [
            {
                "arm_group_label": "DEB TACE", 
                "arm_group_type": "Active Comparator", 
                "description": "Drug eluting Beads (DC Beads) loaded with Doxorubicin"
            }, 
            {
                "arm_group_label": "SIRT", 
                "arm_group_type": "Experimental", 
                "description": "Selective Internal Radiotherapy using Yttrium 90 loaded resin beads (Sir Spheres)"
            }
        ], 
        "brief_summary": {
            "textblock": "Selective Internal Radiotherapy is superior to Transarterial Chemoembolisation for the\n      treatment of intrahepatic cholangiocellular carcinoma (CCC)."
        }, 
        "brief_title": "Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Intrahepatic Cholangiocellular Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Cholangiocarcinoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u226518 years\n\n          -  Intrahepatic CCC, proven by histology or by typical morphology in cross sectional\n             imaging and elevated tumor markers (CEA or CA 19-9)\n\n          -  Tumor confined to the liver\n\n          -  At least one measurable lesion in magnetic resonance imaging (MRI)\n\n          -  Tumor load \u2264 50%\n\n          -  Preserved liver function (Child Pugh A and B)\n\n          -  ECOG performance status \u22642\n\n        Exclusion Criteria:\n\n          -  Patients feasible for curative treatment (e.g. resection or local ablation)\n\n          -  Previous TACE or SIRT\n\n          -  Chemotherapy during the last 4 weeks\n\n          -  Child Pugh stage C\n\n          -  ECOG Performance Status >1\n\n          -  Tumor involvement >50% of the liver\n\n          -  Extrahepatic tumor\n\n          -  Serum Bilirubin >2.0 mg/dl; Serum Albumin 2.8 g/dl, Serum Creatinine >2 mg/dl;\n             Leukocytes <3000/ml; Thrombocytes <50000/ml\n\n          -  Clinically apparent ascites (ascites only in CT/MRI is no exclusion criteria)\n\n          -  Esophageal bleeding during the last 3 months\n\n          -  Hepatic encephalopathy\n\n          -  Transjugular intrahepatic portosystemic shunt (TIPS)\n\n          -  Infiltration or occlusion of the main portal vein\n\n          -  Hepatofugal blood flow in the portal vein\n\n          -  Hepatopulmonary shunt \u2265 20% in the macroaggregated albumin scan (MAA-scan)\n\n          -  Contraindications against angiography\n\n          -  Gravidity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798147", 
            "org_study_id": "SIRT-TACE-CCC-Mainz-1"
        }, 
        "intervention": [
            {
                "arm_group_label": "DEB TACE", 
                "description": "DEB TACE every 6 weeks until either no viable tumor or endpoint reached.", 
                "intervention_name": "DEB TACE", 
                "intervention_type": "Procedure", 
                "other_name": "Chemoembolisation"
            }, 
            {
                "arm_group_label": "SIRT", 
                "description": "Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.", 
                "intervention_name": "SIRT", 
                "intervention_type": "Procedure", 
                "other_name": "Radioembolisation"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cholangiocellular Carcinoma", 
            "TACE", 
            "SIRT"
        ], 
        "lastchanged_date": "March 1, 2014", 
        "location": {
            "contact": {
                "email": "roman.kloeckner@unimedizin-mainz.de", 
                "last_name": "Roman Kloeckner, MD", 
                "phone": "++49613117", 
                "phone_ext": "2019"
            }, 
            "facility": {
                "address": {
                    "city": "Mainz", 
                    "country": "Germany", 
                    "zip": "55131"
                }, 
                "name": "Department of Diagnostic and Interventional Radiology"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).", 
        "overall_contact": {
            "email": "roman.kloeckner@unimedizin-mainz.de", 
            "last_name": "Roman Kloeckner, MD", 
            "phone": "++49613117", 
            "phone_ext": "2019"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "at the end of study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798147"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johannes Gutenberg University Mainz", 
            "investigator_full_name": "Michael Bernhard Pitton", 
            "investigator_title": "Consultant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "at the end of study"
            }, 
            {
                "measure": "Time to progression (TTP)", 
                "safety_issue": "No", 
                "time_frame": "at the end of study"
            }
        ], 
        "source": "Johannes Gutenberg University Mainz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johannes Gutenberg University Mainz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}